🔗 Share this article

Given that the US continues making sweeping changes to its vaccine guidelines, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on Covid vaccines in the global health crisis and has zeroed in on alleged fatalities following Covid immunization in her short position at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Schedule

Public health authorities planned to unveil radical changes to the childhood vaccination calendar recently, aligning the US with the Danish immunization schedule, it is understood – a major change that would put the US at odds with a large portion of the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to lead the division this year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting some childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a society with universal health coverage and a citizenry about the population of Wisconsin’s.

So far public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Qualifications

Høeg has no obvious track record in pharmaceutical research, approval processes or management, which has been typical for previous heads of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a large organization. She is not an expert in drug approvals.”

Previous commissioners of the center would “grasp legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Frankly, she lacks the type of experience that former directors who headed the center have had.”

The drug center has an enormous workload at the agency, Woodcock emphasized.

“Many people just pays attention on the innovative therapies, but the generic drug division clears thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be managed,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the role, which oversees over 5,000 employees. “It’s a enormous management job, if you execute it properly,” she said.

Official Statement and Contentious Programs

Regarding questions about Høeg’s credentials and whether this appointment indicates greater collaboration among agency officials on immunizations, a press secretary said that the “questions are based on incorrect premises”.

“Her resume is consistent with the functions of her role,” the representative said, noting the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day medication authorization process that apparently worried her predecessors. “How are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, except for shots.”

Established History on Vaccines

With immunizations, Dr. Høeg has a more established, if troubling, track record, critics observe. She authored a study using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming government featured changing regulations for new vaccines and discontinuing “optional” immunizations, she stated post-election on a online show. At the FDA, Høeg has allegedly floated the idea of barring young men from obtaining COVID-19 vaccinations.

“She is an thorough dogmatist who begins with her conclusions and reverse-engineers to accommodate the data in a highly disingenuous, dishonest way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|